Risk factors for neuroendocrine tumors of the lung and digestive tract
Risk Factors for Neuroendocrine Neoplasms: a Case-control Study Based on a Record Linkage of Registry and Claims Data
This project will link cancer registry and outpatient health records to try to find medical, lifestyle, and mental-health risk factors for people in Bavaria who develop neuroendocrine tumors of the lung or digestive tract.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 14250 (estimated) |
| Sex | All |
| Sponsor | Bavarian Cancer Registry Government |
| Locations | 1 site (Nuremberg, Bavaria) |
| Trial ID | NCT06282016 on ClinicalTrials.gov |
What this trial studies
This is a population-based case-control analysis using record linkage between the Bavarian Cancer Registry and outpatient claims from the Bavarian Association of Statutory Health Insurance Accredited Physicians. Cases are people diagnosed with neuroendocrine neoplasms of the lung or gastrointestinal tract, and controls are matched individuals without these diagnoses identified from the same insured population. The investigators will examine prior diagnoses (including metabolic disorders and depressive disorders), prescription records (including antidepressant use), and coded lifestyle-related factors such as tobacco and alcohol use as potential risk factors. The goal is to explain part of the recent increase in neuroendocrine neoplasm incidence by identifying associations with medical history and healthcare-recorded behaviors.
Who should consider this trial
Good fit: Ideal candidates are Bavarian residents covered by statutory health insurance who had at least one outpatient physician contact between 2021 and 2023, with cases being those diagnosed with neuroendocrine neoplasms and controls those without such diagnoses.
Not a fit: People living outside Bavaria, those without statutory health insurance coverage, or individuals lacking outpatient records from 2021–2023 are unlikely to be included and therefore would not directly benefit from this dataset-specific analysis.
Why it matters
Potential benefit: If successful, the work could highlight modifiable risk factors and inform prevention, early-detection, and public-health strategies for neuroendocrine tumors.
How similar studies have performed: Previous registry and case-control studies have linked tobacco, alcohol, metabolic conditions, and family cancer history to neuroendocrine tumor risk, but the role of depressive disorders and antidepressant medication remains largely untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Persons with a statutory health insurance (about 85% of the population) and at least one outpatient physician contact in Bavaria between 2021 and 2023 * Residence in Bavaria Exclusion Criteria: * None
Where this trial is running
Nuremberg, Bavaria
- Bavarian Cancer Registry, Bavarian Health and Food Safety Authority — Nuremberg, Bavaria, Germany (Recruiting)
Study contacts
- Principal investigator: Jacqueline Müller-Nordhorn — Bavarian Cancer Registry, Bavarian Health and Food Safety Authority
- Study coordinator: Sven Voigtländer
- Email: sven.voigtlaender@lgl.bayern.de
- Phone: +49-(0)9131-6808
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.